Oculis Holding AG (NASDAQ:OCS) Stock Rated “Moderate Buy” by Wall Street Analysts

Oculis Holding AG (NASDAQ:OCS) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $38.89.

Several brokerages have recently issued reports on OCS. HC Wainwright reiterated a “buy” rating and set a $39.00 price target on shares of Oculis in a report on Wednesday, October 21st. Guggenheim cut their price target on shares of Oculis to $40.00 and set a “buy” rating on the stock in a report on Wednesday. Wall Street Zen upgraded Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research note on Thursday, October 15th. Finally, JPMorgan Chase & Co. lowered their price objective on Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th.

Hedge Funds Weigh In On Oculis

A number of hedge funds have recently bought and sold shares of the company. Braidwell LP purchased a new position in Oculis during the 2nd quarter valued at about $11,570,000. Squarepoint Ops LLC grew its position in Oculis by 326.4% during the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock worth $854,000 after buying an additional 47,158 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Oculis in the 1st quarter valued at $776,000. Alps Advisors Inc. increased its position in Oculis by 40.7% in the 3rd quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock valued at $762,000 after acquiring an additional 23,600 shares during the period. Finally, Himension Capital Singapore PTE. LTD. bought a new position in Oculis during the first quarter valued at approximately $503,000. Institutional investors own 22.30% of the company’s stock.

Oculis Trading Up 9.7%

OCS stock opened at $7.49 on Friday. The business has a 50 day simple moving average of $9.20 and a two-hundred day simple moving average of $18.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.35 and a quick ratio of 8.35. The company has a market capitalization of $434.27 million, a price-to-earnings ratio of -4.38 and a beta of 0.67. Oculis has a 1-year low of $6.78 and a 1-year high of $34.47.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.10. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.26 million. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. Research analysts anticipate that Oculis will post -1.83 EPS for the current fiscal year.

Oculis Company Profile

Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.

Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.